选择性COX-2抑制改善了冠状动脉疾病中的内皮功能
Rémy Chenevard1, David Hürlimann, Markus Béchir
1Cardiovascular Center, Cardiology and Department of Rheumatology, University Hospital Zürich, Switzerland.
Circulation
|January 29, 2003
概括
选择性COX-2抑制,就像塞莱科西布一样,改善了冠状动脉疾病患者的血管功能和减少了炎症. 这表明这些药物对高危患者的潜在心血管益处.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 炎症研究 炎症研究
背景情况:
- 关于COX-2抑制剂与NSAIDs的心血管安全性的持续辩论.
- 在高危患者中,需要评估选择性COX-2抑制对心血管疾病替代品,特别是内皮功能的影响.
研究的目的:
- 确定选择性COX-2抑制对冠状动脉疾病患者内皮功能和炎症标志物的影响.
主要方法:
- 这是一项双盲,安慰剂控制,交叉研究,涉及14名患有严重冠状动脉疾病的男性患者,他们在背景阿司匹林和他类药物治疗中.
- 患者接受了赛莱科克西布 (200毫克两次) 或安慰剂2周.
- 评估了流媒体臂动脉扩张,高灵敏度C反应蛋白,氧化LDL和前列腺素.
主要成果:
- 与安慰剂相比,切莱科克西布显著改善了内皮依赖的血管扩张 (3.3%对2.0%,P=0.026).
- 内皮独立的血管扩张保持不变.
- 切莱科克西布降低了高灵敏度C反应蛋白 (1.3 mg/L与1.8 mg/L相比,P=0.019) 和氧化的LDL (43.6 U/L与47.6 U/L相比,P=0.028).
结论:
- 这是第一个表明选择性COX-2抑制改善冠状动脉疾病患者内皮功能的研究.
- 选择性COX-2抑制减少了慢性炎症和氧化应激.
- 这些发现表明选择性COX-2抑制剂对心血管结果的潜在有益影响.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.9K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
615
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
615
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.7K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.7K
Coronary Artery Disease II: Pathophysiology
1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
Coronary Artery Disease V: Interprofessional Care
444
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444


